In collaboration with a Stanford University research team, Scenic Biotech identified and characterized PLA2G15 as a novel target in lysosomal storage diseases ...

With this appointment, Pramana further strengthens its world-class scientific team spanning metabolic disease, cardiovascular biology, and neurology. Together, this group is advancing a bold vision: ...

Note: alfa pump® and DSR® are registered trademarks.

The decision was taken following a plenary meeting of the Pharmacovigilance Risk Assessment Committee (PRAC) on May 5, 2025 and is based on reports of 17 SAEs worldwide (including two deaths) in ...

Currently, PH is primarily diagnosed through right heart catheterization (RHC), an invasive and resource-intensive procedure. Transthoracic echocardiography (TTE), while commonly used as a screening ...

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity ...

Trogenix Further Strengthens its Scientific Advisory Board with the Appointment of World-Leading Experts, Prof Nada Jabado and Prof Burkhard Becher ...

Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in Las Vegas. Krish S.

A live webcast of the presentation can be accessed under “ News and Events ” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the presentation will be ...

A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

To register for one-on-one meetings with management in New York City, interested parties should contact John Perez at jperez@dboralcapital.com.

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...